Business Context and Reporting Period
This Form 8-K is filed by Emerald Bioscience, Inc. (not Skye Bioscience, Inc.) for the reporting date of June 17, 2020. The filing discloses a specific financing event involving a drawdown under an existing credit facility.
Key Financial Metrics
- Transaction Amount: $300,000 (Fifth Drawdown).
- Total Debt Drawn: $6,150,000 as of June 17, 2020.
- Credit Facility Limit: $20,000,000 revolving credit facility.
- Interest Rate: 7% per annum.
- Maturity Date: October 5, 2022.
- Security Status: Unsecured.
- Use of Proceeds: General corporate and working capital purposes.
Note: The filing does not provide data on revenue, profit, cash flow, or margins.
Material Changes
The Company executed a fifth drawdown of $300,000 under the Multi-Draw Credit Agreement with Emerald Health Sciences Inc. (EHS). This action increased the total principal amount drawn from the facility to $6,150,000. Unlike previous potential terms, EHS elected that this specific drawdown will not be convertible into common stock and no warrants will be issued in connection with this transaction.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard terms of the debt agreement. The primary contingency noted is the maturity of the loan on October 5, 2022, unless earlier converted (though conversion was explicitly declined for this specific drawdown).
Investor Verification Checklist
- Verify the total outstanding debt balance of $6,150,000 against the company's most recent 10-Q or 10-K.
- Confirm the remaining availability under the $20,000,000 credit facility ($13,850,000).
- Review the full text of the Credit Agreement (Exhibit 10.1 from the April 29, 2020 filing) for covenants and default provisions.
- Monitor the company's cash burn rate to assess liquidity needs prior to the October 2022 maturity date.